Generation Bio
Engages in developing genetic medicines through gene therapy platform for intrinsic hepatic diseases and systemic diseases.
Launch date
Employees
Market cap
€158m
Enterprise valuation
€46m (Public information from Sep 2024)
Share price
$2.86 GBIO
Cambridge Massachusetts (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | 5.9m | 11.5m | 6.5m | 10.6m |
% growth | - | - | - | - | 95 % | (44 %) | 63 % |
EBITDA | (81.1m) | (119m) | (141m) | (133m) | - | - | - |
% EBITDA margin | - | - | - | (2258 %) | - | - | - |
Profit | (80.5m) | (119m) | (137m) | (127m) | (119m) | (75.6m) | (73.8m) |
% profit margin | - | - | - | (2145 %) | (1029 %) | (1163 %) | (698 %) |
EV / revenue | - | - | - | -26.3x | -0.7x | 27.1x | 16.7x |
EV / EBITDA | -15.9x | -3.4x | -1.6x | 1.2x | - | - | - |
R&D budget | 58.5m | 85.2m | 96.7m | 93.6m | - | - | - |
R&D % of revenue | - | - | - | 1586 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
$25.0m | Series A | ||
$25.0m | Series A | ||
$100m | Series B | ||
* | $110m | Series C | |
N/A | N/A | IPO | |
* | N/A | $225m | Post IPO Equity |
* | $36.0m | Post IPO Equity | |
Total Funding | €236m |
Recent News about Generation Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.